Envoy Medical Secures $78M Upsized Offering, Extends Cash Runway to 2027
Envoy Medical closed an upsized $78.0 million public offering priced at $0.40 per share and warrant, raising $30.0 million upfront with potential for an additional $48.0 million upon full warrant exercise. The net proceeds extend the company’s cash runway into late 2027 and beyond commercial launch if milestones are met.
1. Offering Structure and Proceeds
Envoy Medical issued 75 million Class A common stock units, including Series A-1 warrants for 45 million shares and Series A-2 warrants for 75 million shares, priced at $0.40 each. Gross proceeds were approximately $30.0 million, with up to $48.0 million additional if all warrants are exercised.
2. Investor Backing and Upsize
The upsized offering was anchored by Nantahala Capital with participation from healthcare-dedicated funds including Broadfin Holdings, existing shareholder Glen Taylor, and company directors and management. H.C. Wainwright & Co. served as exclusive placement agent for the transaction.
3. Cash Runway and Future Milestones
Net proceeds extend Envoy’s cash runway into the second half of 2027, carrying the company beyond its planned PMA submission. If milestone-linked warrants are fully exercised, the runway could extend past FDA approval and into the first full year of commercialization.